Reboxetine is a selective noradrenergic reuptake inhibitor that displays an antidepressant profile in both animal tests and in clinical trials. The present study examined the ability of reboxetine to alter stress-induced increases in norepinephrine, serotonin and dopamine efflux in the frontal cortex in awake behaving rats. Acute systemic administration of reboxetine (0.3-20.0 Despite widespread efforts to understand the mechanisms of action of antidepressant drugs, the requisite changes in neural function that underlie their therapeutic effects remain unclear. Much evidence exists that points to dysfunction of the norepinephrine (NE), serotonin (5-HT) and dopamine (DA) neurotransmitter systems in depression. For example, it is known that drugs that alter monoamine neurotransmission provide some relief of depressive symptomatology. However, the pathophysiology associated with this disorder is not clear (Heninger and Charney 1987;Ressler and Nemeroff 2000;Schildkraut 1965). Furthermore, the acute pharmacological actions of many compounds at biogenic amine transporter sites do not account for the delay in onset of therapeutic effects. A therapeutic response is typically only observed following chronic treatment regardless of the particular class of drug or mode of treatment (Blier and DeMontigny 1994). A number of studies suggest that functional changes in receptor sensitivity following antidepressant treatment are required and may account, at least in part, for the therapeutic lag observed. For example, the downregulation of a variety of receptor subtypes, including  -and (Blier and DeMontigny 1994).In the past, traditional antidepressant compounds such as the tricyclics were known to increase synaptic availability of NE, and thus an emphasis on the role of NE in both the pathogenesis of affective disorders and in the mechanism of action of antidepressant medications has driven much of the work in this field (Frazer 2000;Schildkraut 1965). However, most tricyclic compounds are associated with a large adverse side effect profile that contributes to low compliance among patients (Frazer 2000). The advent of the selective serotonin reuptake inhibitors (SSRIs), which have a lower side-effect profile, shifted the emphasis toward a potential crucial role of serotonergic dysfunction in affective disorders. Although a reduction in side effects associated with SSRIs has contributed to their popularity, many patients remain treatment resistant. A continuing effort to identify more efficacious antidepressant compounds has led to the emergence of the selective NE reuptake inhibitors (see Brunello and Racagni 1998). Reboxetine selectively inhibits the reuptake of synaptic NE without any marked affinity for other receptors or transporters (Wong et al. 2000). Additionally, reboxetine has been shown to be both clinically effective and well tolerated with a lower side-effect profile than tricyclics (Burrows et al. 1998).The present studies sought to characterize the impact of reboxetine treatment on monoaminergic neurotransmis...